Ranbaxy can give high returns but extremely risky: Dron Cap

Oct 05, 2013, 03.17 PM IST

Pathik Gandotra of Dron Capital feels Ranbaxy Labs can also give a very high return, but it is extremely risky, he adds.

Like this story, share it with millions of investors on M3

Pathik Gandotra of Dron Capital feels Ranbaxy Labs can also give a very high return, but it is extremely risky, he adds.

Like this story, share it with millions of investors on M3

Ranbaxy can give high returns but extremely risky: Dron Cap

Pathik Gandotra of Dron Capital feels Ranbaxy Labs can also give a very high return, but it is extremely risky, he adds.

. Share . Email . Print . A+A-

Pathik Gandotra of Dron Capital told CNBC-TV18, "In case of Ranbaxy Laboratories , it is very risky because three of its plants are shut; the fourth one has got a 483 form. So I would be very scared. Although I do believe that since its fourth facility is in the US, the plant may not shut. If the plant does perform then they can get their products rolling."

"It is a long-term story. The valuation is right, but the risk is too high. If there is some event happening on the fourth plant then there can be a serious issue. Otherwise everything was going on well for it till the Mohali import alert came and then 483 on the Ohm Laboratories. It can also give a very high return, but it is extremely risky," Gandotra said.

Untuk Kesehatan